Absci · Company profile

Public reviewed developments

1. Absci 公布 AI 设计抗体 ABS-201 的 II 期试验初步计划

   Thu Sep 24 2026 12:00:49 GMT+0000 (Coordinated Universal Time) · 1 currently public evidence items

   据 Absci 官方公告，AI 设计抗体 ABS-201 的 II 期试验预计于 2027 年中启动。当前披露为初步计划，不能写成 II 期已经开展。

   Absci

   Inspect event evidence →

Collaboration, licensing, and acquisition timeline

No collaboration, licensing, or acquisition nodes appear in the developments shown here. This does not establish that the company has never had such activity.

These are drawn from the latest 1 reviewed developments. A collaboration, model performance, experimental results, and clinical progress each require their own evidence.

Public source records

• Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis

  Absci official news RSS · Indexed industry source record · Source published: Thu Sep 24 2026 12:00:49 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)

  Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER

  Original sources

• Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

  Absci official news RSS · Indexed industry source record · Source published: Tue Jul 14 2026 20:05:30 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)

  VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announc

  Original sources

• Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

  Absci official news RSS · Indexed industry source record · Source published: Wed Jun 24 2026 10:30:27 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)

  Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval o

  Original sources

• Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026

  Absci official news RSS · Indexed industry source record · Source published: Thu Apr 23 2026 20:04:58 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)

  VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announ

  Original sources

Verified official and subscription sources

• Absci official news RSS · Collection enabled · Last successful collection Fri Oct 09 2026 07:07:44 GMT+0000 (Coordinated Universal Time)

Source verification and ongoing collection are shown separately. Indexed source records do not automatically become reviewed events.